C
Lagging
Injectable division · GLP-1/glucagon dual
Survodutide
Boehringer Ingelheim · once weekly
Certifiedthe cautionary tale
Division standing
#5 of 5
Injectable division
← Tolerability cost (bands)% body weight lost →
Heavy: GI08% vs placebo
Tolerability: the cost
Heavy20.2% vs 2.9% placebo
AE-discontinuation +17.3 points, GI-specific (total any-AE not disclosed), at the 6.0 mg weekly. From SYNCHRONIZE-1.
Efficacy
8%6.0 mg · placebo-adjusted · 76 wk
SYNCHRONIZE-1: 13% vs 5.4% placebo, an 8-point gap on the treatment-regimen estimand. The efficacy estimand runs 13.4 points.
The cautionary tale: a headline built on the flattering number, and the toughest on this board to stay on.
The 16.6% headline is the efficacy estimand. On treatment-policy it is 13.0% vs a high 5.4% placebo, a 7.6 point difference, because the dropout shows up.
The discontinuation figure is GI-specific; total any-AE discontinuation was not disclosed. It is already enough for the Heavy band.
Convenience profile: you weigh it, not us
Route
Subcutaneous injection
Frequency
Once weekly
Food / water rule
None
Titration
Multi-step escalation over several months
Storage
Refrigerated
Provenance: every number traces back
TrialSYNCHRONIZE-1 · NCT06066515
Estimandtreatment-regimen estimand (efficacy estimand labeled)
Populationnon-diabetic obesity
Dose6.0 mg weekly
SourceNEJM 2026
Verdict confirmed5 Jul 2026
Next milestone: Full SYNCHRONIZE Phase 3 program readoutsMechanism field guide →